Amgen Inc. (43)

Browse by Contract Category

Contracts

Officers Certificate of the Company, dated as of August 9, 2021, including forms of the Companys 1.650% Senior Notes due 2028, 2.000% Senior Notes due 2032, 2.800% Senior Notes... (Filed With SEC on August 9, 2021)
Amended and Restated Collaboration Agreement, dated June 2, 2021, by and between Amgen Inc. and Novartis Pharma AG (Filed With SEC on August 4, 2021)
Agreement and Plan of Merger, dated as of March 4, 2021, by and among Amgen Inc., Franklin Acquisition Sub, Inc. and Five Prime Therapeutics, Inc (Filed With SEC on March 4, 2021)
Amgen Inc. 2009 Director Equity Incentive Program. (As Amended (Filed With SEC on February 9, 2021)
Description of Amgen Inc.s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 9, 2021)
Underwriting Agreement, dated August 5, 2021, by and among the Company and Citigroup Global Markets Inc., Morgan Stanley & Co. LLC, Barclays Capital Inc. and Goldman Sachs & Co.... (Filed With SEC on August 9, 2021)
Amendment No. 7 to the Collaboration Agreement, dated December 18, 2020, by and between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC (Filed With SEC on February 9, 2021)
Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended on December 1 (Filed With SEC on February 9, 2021)
Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December (Filed With SEC on February 9, 2021)
Form of Grant of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 1 (Filed With SEC on February 9, 2021)
Amendment No. 2 to the Collaboration Agreement, dated August 19, 2020, by and between Amgen Inc. and Novartis Pharma AG (Filed With SEC on October 29, 2020)
Restated Amendment No. 2 to Share Purchase Agreement, dated September 24, 2020, by and among BeiGene, Ltd. and Amgen Inc (Filed With SEC on October 29, 2020)
Registration Rights Agreement, dated as of August 17, 2020, by and among the Company, BofA Securities, Inc. and J.P. Morgan Securities LLC, as lead dealer managers, and BNP... (Filed With SEC on August 18, 2020)
Officers Certificate of Amgen Inc., dated as of August 17, 2020, including forms of the Companys 2.770% Senior Notes due 2053 (Filed With SEC on August 18, 2020)
Amendment Nos. 2 through 6 to the March 30, 2012 Collaboration Agreement between Amgen Inc. and AstraZeneca Collaboration Ventures, LLC, dated May 2 and 27 and October 2, 2016,... (Filed With SEC on July 29, 2020)
Officers Certificate of the Company, dated as of May 6, 2020, including the form of the Companys 2.300% Senior Notes due 2031 (Filed With SEC on May 6, 2020)
Underwriting Agreement, dated as of May 4, 2020, by and among the Company and BofA Securities, Inc., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC and Morgan Stanley &... (Filed With SEC on May 6, 2020)
Amendment No. 2 to Share Purchase Agreement, dated March 17, 2020, by and among BeiGene, Ltd. and Amgen Inc (Filed With SEC on May 1, 2020)
Side Letter Regarding Collaboration Agreement and Stivarga Agreement, dated February 13, 2020, by and between Onyx Pharmaceuticals, Inc. and Bayer HealthCare LLC (Filed With SEC on May 1, 2020)
Agreement between Amgen Inc. and Peter Griffith, dated October 18, 2019 (Filed With SEC on May 1, 2020)
Underwriting Agreement, dated February 18, 2020, by and among the Company and Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, Barclays Capital Inc. and Morgan Stanley &... (Filed With SEC on February 21, 2020)
Officers Certificate of the Company, dated as of February 21, 2020, including forms of the Companys 1.900% Senior Notes due 2025, 2.200% Senior Notes due 2027, 2.450% Senior Notes... (Filed With SEC on February 21, 2020)
Letter Agreement, dated November 21, 2019, by and between Amgen Inc. and the parties named therein re: Treatment of Certain Product Inventory in connection with Amgens acquisition... (Filed With SEC on February 12, 2020)
Collaboration Agreement, dated October 31, 2019, by and between Amgen Inc. and BeiGene Switzerland GmbH, a wholly-owned subsidiary of BeiGene, Ltd (Filed With SEC on February 12, 2020)
Form of Restricted Stock Unit Agreement for the Amgen Inc. 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.) (Filed With SEC on February 12, 2020)
Amendment No. 2 to the Asset Purchase Agreement, dated October 17, 2019, by and between Amgen Inc. and Celgene Corporation (Filed With SEC on February 12, 2020)
Description of Amgen Inc.s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 12, 2020)
Form of Grant of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 10, 2019.) (Filed With SEC on February 12, 2020)
Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 10, 2019.) (Filed With SEC on February 12, 2020)
Amgen Inc. 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.) (Filed With SEC on February 12, 2020)
Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended on December 10, 2019.) (Filed With SEC on February 12, 2020)
Form of Cash-Settled Restricted Stock Unit Agreement for the Amgen 2009 Director Equity Incentive Program. (As Amended on December 11, 2019.) (Filed With SEC on February 12, 2020)
Second Amendment to the Amgen Inc. Supplemental Retirement Plan (As Amended and Restated effective October 23, 2019) (Filed With SEC on February 12, 2020)
Second Amendment to the Amgen Nonqualified Deferred Compensation Plan (As Amended and Restated effective January 1, 2020) (Filed With SEC on February 12, 2020)
Guarantee, dated as of October 31, 2019, made by and among BeiGene, Ltd. and Amgen Inc (Filed With SEC on February 12, 2020)
Second Amended and Restated Credit Agreement, dated as of December 12, 2019, among Amgen Inc., the Banks therein named, Citibank, N.A., as Administrative Agent, and JPMorgan Chase... (Filed With SEC on December 12, 2019)
Amendment No. 1 to the Asset Purchase Agreement, dated August 25, 2019, by and between Amgen Inc. and Celgene Corporation (Filed With SEC on October 18, 2019)
Asset Purchase Agreement, dated August 25, 2019, by and between Amgen Inc. and Celgene Corporation (Filed With SEC on August 26, 2019)
Irrevocable Guarantee, dated August 25, 2019, by and between Amgen Inc. and Bristol-Myers Squibb Company (Filed With SEC on August 26, 2019)
Letter Agreement, dated June 25, 2019, by and between Amgen Inc. and UCB Celltech (portions of the exhibit have been omitted because they are both (i) not material and (ii) would... (Filed With SEC on July 31, 2019)
Form of Restricted Stock Unit Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 7, 2018.) (Filed With SEC on February 13, 2019)
Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award Program. (As Amended on December 7, 2018.) (Filed With SEC on February 13, 2019)
Form of Stock Option Agreement for the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan. (As Amended on December 7, 2018.) (Filed With SEC on February 13, 2019)